In theory, those opposed to early treatments could publish a competing analysis of studies on early treatments. Maybe that has already been done?
On some contested topics, there's almost a need for rules of evidence, so there's an agreed upon list of papers/data for discussion. Then different stakeholders/teams can debate on their (likely biased) interpretations of a pool of evidence that is clearly bounded at any point in time, but expanding as new data/studies become available.
I was curious so I ran Whois queries on three sites: c19early.com which you linked, and ivmmeta.com and c19ivermectin.com. They all seem to be hosted through google sites, and use the same DNS privacy service. I don’t know if google sites by default uses this service or something, but just looking at the similarity of the sites I am wary.
[0]: https://blogs.sciencemag.org/pipeline/archives/2021/06/07/iv...
When experiments don't match our predictions, there is often either an error in the experiment, or an opportunity to improve the models behind the prediction. In this case, one of the experiments (UP with 200 million people) apparently has an unexpectedly good, positive, cheap outcome with minimal supply chain dependencies or safety risks.
If the observations are incorrect, that should be easy to establish.
If we are unable to explain this observed, positive, practical outcome via existing theory, that would be scientifically exciting!
It seems like there are several sites that all have similar layout/content and very distinctive plot styling. I think they are related, but I’m on a phone and haven’t made time for dig queries and such. Seems dodgy though.
Anyway, there’s been a feeding frenzy of questionable research since the pandemic started (well especially so anyway) so it’s more important than ever to practice informed skepticism.
[0]: https://news.ycombinator.com/item?id=28177264